Clinical trial
Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With…
NCT00080015 · Ipsen, Industry · Completed
Key facts
| NCT number | NCT00080015 |
|---|---|
| Title | Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC) |
| Official title | A Phase II Open Label Study Investigating the Activity of Diflomotecan (BN80915) Administered at the Fixed Dose of 7mg as a 20 Minute Intravenous Infusion Once Every 3 Weeks in Patients With Sensitive Small Cell Lung Cancer (SCLC) Who Have Failed First-line Treatment With a Platinum Based Regimen. |
| Lead sponsor | Ipsen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Diflomotecan (BN80915) |
| Enrollment | 9 |
| Start date | Mar 12, 2004 |
| Primary completion | Feb 1, 2005 |
| Completion | Feb 1, 2005 |
| First posted | Mar 23, 2004 |
| Last update posted | Apr 29, 2020 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: